secwatch.observer — SEC 8-K summary
======================================

Issuer:     PDS Biotechnology Corp (PDSB)
CIK:        0001472091
Form:       8-K
Filed at:   2021-10-06T23:59:59+00:00
Accession:  0001140361-21-033839
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 5.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

PDS Biotech terminates CFO, hires Hill; completes Phase 2 enrollment in head and neck cancer
--------------------------------------------------------------------------------

- CFO Seth Van Voorhees terminated without cause Sept 30; CEO Bedu-Addo interim CFO, controller Trochimiuk interim PAO.
- Matthew Hill appointed CFO effective Oct 18; salary $350k, 35% bonus, severance 12 mo base, inducement option for 202,800 shares.
- Completed enrollment of first stage of CPI-naïve arm in VERSATILE-002 Phase 2 study for HPV16 head and neck cancer.
- If >=4 of first 17 patients achieve objective response per RECIST 1.1, arm advances to second stage with total 54 patients; trial with Merck.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1472091/000114036121033839/0001140361-21-033839-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1472091/000114036121033839/brhc10029650_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-21-033839

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer